UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.)*

Maravai LifeSciences Holdings, Inc.										
			(Name of Issuer)							
			Class A Common Stock, par value \$0.001 per share							
			(Title of Class of Securities)							
			56600D107 (CUSIP Number)	_						
			, ,							
			December 31, 2020 (Date of Event Which Requires Filing of this Statement)							
Check the approp	riate box to	desig	gnate the rule pursuant to which this Schedule is filed:							
✓ Rule 13c☐ Rule 13c	` /									
☐ Rule 13c										
			cover page shall be filled out for a reporting person's initial filing on this form with respect	to the subject class of securities, and for any						
subsequent amen	dment contai	ining	information which would alter the disclosures provided in a prior cover page.							
			in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section liabilities of that section of the Act but shall be subject to all other provisions of the Act (howe							
(Act) of otherw	ise subject it	o uic	natifices of that section of the Act out shall be subject to an other provisions of the Act (now	wei, see the Notes).						
CUSIP No. 5660	00D107		SCHEDULE 13G	Page 2 of 7						
1	NAME OF	REP	ORTING PERSON							
	D1 Capital 1	Partı	ners L.P.							
2	CHECK TH	HE A	PPROPRIATE BOX IF A MEMBER OF A GROUP	(a) □ (b) □						
				(6) 🗆						
3	SEC USE C)NL	Υ ·							
	CITIZENIA	(III)	OD DV 4 GD OF ODG 4 VYZ 4 TYOV							
4	CHIZENSI	HIP	OR PLACE OF ORGANIZATION							
	Delaware	5	SOLE VOTING POWER							
		3	SOLE VOTINGTOWER							
NUMBEI	R OF	6	0 SHARED VOTING POWER							
SHARI	ES									
BENEFICIALL BY EACH RE		7	5,930,000 SOLE DISPOSITIVE POWER							
PERSO WITH										
Will	1	8	SHARED DISPOSITIVE POWER							
			5,930,000							
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON									
	5,930,000									
10	/ /	OX I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)									
	6.1%									
12	TYPE OF R	REPO	ORTING PERSON							
	PN, IA									

CUSIP No. 56	600D107	SCHEDULE 13G	Page 3 of 7					
1	NAME OF	REPORTING PERSON						
	Daniel Sund	theim						
2		IE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗆					
			(b) □					
3	SEC USE C	ONLY						
4	CITIZENSI	HIP OR PLACE OF ORGANIZATION						
İ	United State	es of America						
		5 SOLE VOTING POWER						
		0						
NUMB		6 SHARED VOTING POWER						
SHA BENEFICIAI	LLY OWNED	5,930,000						
BY EACH R		7 SOLE DISPOSITIVE POWER						
	TH	0						
		8 SHARED DISPOSITIVE POWER						
		5,930,000						
9	AGGREGA	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	5,930,000							
10	CHECK BO	OX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	6.1%							
12	TYPE OF F	TYPE OF REPORTING PERSON						
	IN, HC							
CUSIP No. 56	6600D107	SCHEDULE 13G	Page 4 of 7					
Item 1(a).	Name of Iss	suer.						

Maravai LifeSciences Holdings, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices.

10770 Wateridge Circle, Suite 200 San Diego, CA 92121

Item 2(a). Name of Person Filing.

This statement is filed by D1 Capital Partners L.P. (the "Investment Manager") and Daniel Sundheim (the "Mr. Sundheim"). The foregoing persons are hereinafter sometimes referred to as the "Reporting Persons."

The Investment Manager is a registered investment adviser and serves as the investment manager of private investment vehicles and accounts, including D1 Capital Partners Master LP (the "Investment Vehicle"). Mr. Sundheim may be deemed to beneficially own the reported securities by virtue of the fact that Mr. Sundheim indirectly controls the Investment Manager.

The filing of this statement should not be construed as an admission that any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the securities reported herein.

Item 2(b). Address of Principal Business Office.

	Daniel Sundhein									
	c/o D1 Capital Partners L.P. 9 West 57 th Street, 36 th Floor									
	New York, New	York 10019								
Item 2(c).	Place of Organi	ization.								
	Investment Manager – Delaware Mr. Sundheim – United States of America									
Item 2(d).	Title of Class of	f Securities.								
	Class A common	n stock, \$0.001 par value (the 'Common Stock')							
Item 2(e).	CUSIP Number	r.								
	56600D107									
			_	_	_					
CUSIP No. 56	6600D107]	SCHEDULE 13G		Page 5 of 7					
Item 3.	If this Statemen	If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:								
	(a) 🗆		ed under section 15 of the Act (15 U.S.C. 7	⁷ 80);						
	(b)		on 3(a)(6) of the Act (15 U.S.C. 78c); efined in section 3(a)(19) of the Act (15 U.S.C. 78c)	S.C. 78c);						
	(d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);									
	 (e) ⊠ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); (f) □ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); 									
	(g) ⊠ (h) □		any or control person in accordance with §2 defined in Section 3(b) of the Federal Depo							
	(i)	A church plan that is exc (15 U.S.C. 80a-3);	cluded from the definition of an investment	company under section 3(c)(14) of the	he Investment Company Act of 1940					
	(i) □ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); (k) □ Group, in accordance with §240.13d-1(b)(1)(ii)(K).									
	If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:									
	Not applicable.									
Item 4.	Ownership.									
	The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentages set forth in this Schedule 13G are calculated based upon an aggregate of 96,646,515 Common Stock outstanding as of November 23, 2020, as reported in the Issuer's final prospectus filed pursuant to rule 424(b)(4).									
Item 5.	Ownership of Five Percent or Less of a Class.									
	Not applicable.									
CUSIP No. 56	6600D107]	SCHEDULE 13G		Page 6 of 7					
Item 6.	Ownership of M	More Than Five Percent o	on Behalf of Another Person.							
	The Investment Vehicle has the right to receive and the power to direct the receipt of dividends from, and the proceeds from the sale of, the Common Stock.									
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Cor Person.									
	Not applicable.									
Item 8.	Identification a	nd Classification of Mem	abers of the Group.							
	Not applicable.									
Item 9.	Notice of Dissol	lution of Group.								
	Not applicable.									

D1 Capital Partners L.P. 9 West 57th Street, 36th Floor New York, New York 10019

Item 10. Certification.

By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 56600D107

SCHEDULE 13G

Page 7 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 16, 2021

D1 CAPITAL PARTNERS L.P.

By: /s/ Amanda Hector

Name: Amanda Hector

Title: General Counsel and Chief Compliance Officer

/s/ Daniel Sundheim

DANIEL SUNDHEIM

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Date: February 16, 2021

D1 CAPITAL PARTNERS L.P.

By: /s/ Amanda Hector

Name: Amanda Hector

Title: General Counsel and Chief Compliance Officer

/s/ Daniel Sundheim

DANIEL SUNDHEIM